Active Cancer NIHR-supported project Brain & Nervous System

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Funder NIHR (part of DHSC)
Recipient organisation NIHR Biomedical Research Centre at the Royal Marsden and the ICR Source-published name: NIHR Royal Marsden Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Feb 2025 — May 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Johann De Bono (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 as a Single Agent and in Combination with the ATR Inhibitor Tuvusertib in Participants with Advanced Solid Tumors.

Original classification

Early Phase Drug Development

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.